Management of Acute Heart Failure during an Early Phase
- PMID: 36263292
- PMCID: PMC9536658
- DOI: 10.36628/ijhf.2019.0014
Management of Acute Heart Failure during an Early Phase
Abstract
Acute heart failure (AHF), a global pandemic with high morbidity and mortality, exerts a considerable economic burden. AHF includes a broad spectrum of clinical presentations ranging from new-onset heart failure to cardiogenic shock. Key elements of the management rely on the clinical diagnosis confirmed on, both, increased natriuretic peptides and echocardiography, and on the prompt initiation of oxygen therapy, including non-invasive positive pressure ventilation, vasodilators, and diuretics. A care pathway is essential, specifically when an acute coronary syndrome is suspected or in the case of cardiogenic shock. Association or increasing doses of vasopressors despite an adequate volume status are markers of progression toward a refractory cardiogenic shock state. For the latter, mechanical circulatory support should be initiated early, optimally before the onset of renal or liver failure. Thus, a tertiary care center is recommended for the management of patients with AHF who require percutaneous coronary intervention or mechanical circulatory support. This narrative review provides multidisciplinary guidance for the management of AHF and cardiogenic shock from pre-hospital to intensive care unit/cardiac care unit, based on contemporary evidence and expert opinion.
Keywords: Cardiogenic shock; Emergency; Heart failure; Therapeutics.
Copyright © 2020. Korean Society of Heart Failure.
Conflict of interest statement
Conflict of Interest: Koji Takagi received speaker's honoraria from Otsuka, Sumitomo Dainippon, AstraZeneca, and Bayer and consultancy fees from Terumo. Antoine Kimmoun received a speaker's honoraria from Baxter, MSD, and Gilead. Naoki Sato has been a consultant for Otsuka, Terumo, Novartis, Toa-Eiyo, Tanabe-Mitsubishi, and BMS, and has received honoraria from Otsuka, Ono, Daiichi-Sankyo, Teijin, Boehringer Ingelheim, and Bayer. Alexandre Mebazaa reports personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips, grants and personal fees from Adrenomed, Abbott, grants from 4TEEN4.
Figures
References
-
- Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488. - PubMed
-
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. - PubMed
-
- Van Aelst LN, Arrigo M, Placido R, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20:738–747. - PubMed
-
- Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36:S129–39. - PubMed
-
- Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
